☆ 4.6 Review

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases

CANCERS (2021)

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint

Peiyu Zhu et al.

Summary: A novel series of isoxazole-containing biphenyl compounds were designed, synthesized, and evaluated as PD-1/PD-L1 inhibitors, showing promising inhibitory activities against the protein-protein interactions. Compound II-12 was identified as a potential anti-PD-1/PD-L1 inhibitor with valuable information for future drug development. The study demonstrated the advantages of small-molecule PD-1/PD-L1 inhibitors as a complement to monoclonal antibodies in cancer immunotherapy.

MOLECULAR DIVERSITY (2022)

Add to Collection
Review Pharmacology & Pharmacy

Immune Checkpoint Inhibitors in the Treatment of Cancer

Wissam Zam et al.

Summary: Immune checkpoint inhibitors (ICIs) are drugs that work by blocking checkpoint proteins. CTLA-4 and PD-1 are the two main targeted pathways in clinical practice. This review provides an updated comprehensive analysis of the use of ICIs in various types of cancer, highlighting their efficacy and adverse effects.

CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY (2022)

Add to Collection
Article Medicine, Research & Experimental

Increased Expression ofPD-1 andPD-L1in Patients With Laryngotracheal Stenosis

Ruth J. Davis et al.

Summary: Recent evidence suggests that dysregulated host immunity plays a role in the development and progression of laryngotracheal stenosis (LTS). The PD-1/PD-L1 axis, targeted by immunotherapies for cancer treatment, is also implicated in the pathogenesis of fibrotic pulmonary disease. Elevated expression of PD-1 and PD-L1 in LTS patients suggests a possible role for checkpoint inhibitors targeting this axis in LTS treatment.

LARYNGOSCOPE (2021)

Add to Collection
Article Gastroenterology & Hepatology

The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer

Jin Won Kim et al.

Summary: The study revealed a positive correlation between sTGF-beta and sPDL1 in BTC patients, and an elevated sTGF-beta value after treatment was associated with worse prognosis in terms of DFS and OS, as well as shorter overall survival.

LIVER INTERNATIONAL (2021)

Add to Collection
Article Biochemical Research Methods

Network-based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients

Tasnimul Alam Taz et al.

Summary: The study focused on the synergistic effect between SARS-CoV-2 and IPF patients, revealing common genes, pathways, and drug targets through transcriptomic analysis and protein interaction network. The findings suggest that SARS-CoV-2 infection may lead to increased mortality for IPF patients, providing new insights for treatment.

BRIEFINGS IN BIOINFORMATICS (2021)

Add to Collection
Article Oncology

Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer

Chaoyan Wang et al.

Summary: This study investigated the distinct functions of different PD-L1 isoforms in colorectal cancer (CRC) and found that isoform b can be considered as a biomarker for responsiveness to anti-PD-1/PD-L1 immunotherapy, while isoform c has a prometastatic role in CRC.

CANCER SCIENCE (2021)

Add to Collection
Article Biochemical Research Methods

PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies

Julius Benicky et al.

Summary: Immune checkpoint inhibitors, such as PD-L1/PD-1, play crucial roles in regulating immune responses and are promising targets for cancer immunotherapy. The glycosylation of PD-L1, particularly at the N219 sequon, influences its interaction with PD-1, with complex glycans and polyLacNAc structures being predominant. Different forms of PD-L1 exhibit varying N219 occupancy and polyLacNAc contributions, potentially impacting their interactions with PD-1.

JOURNAL OF PROTEOME RESEARCH (2021)

Add to Collection
Article Oncology

Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis

Roberta Carosio et al.

Summary: This study found variable expression of sPD-L1 in PE, with higher levels in patients with PD-L1-positive tumors. sPD-L1 levels were significantly higher than sPD-1 levels regardless of MPM histotypes, and the two were positively correlated. Additionally, higher PE sPD-L1 concentrations were associated with a trend towards increased OS in MPM patients.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection
Review Cell Biology

Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets

Benhui Liang et al.

Summary: The binding of PD-1 to its ligand PD-L1 is crucial for maintaining the non-reactivity of T cells, while tumor cells restrict cellular immune response by highly expressing PD-L1. TEXs can carry PD-L1 and regulate the PD-1/PD-L1 axis to promote tumor progression.

JOURNAL OF CELLULAR PHYSIOLOGY (2021)

Add to Collection
Article Oncology

Atezolizumab alleviates the immunosuppression induced by PD-L1-positive neutrophils and improves the survival of mice during sepsis

Jianxin Chen et al.

Summary: The study found that treatment with atezolizumab can effectively alleviate immunosuppression induced by sepsis in a mouse model, reducing endotoxin concentration, improving intestinal permeability, and potentially prolonging survival time.

MOLECULAR MEDICINE REPORTS (2021)

Add to Collection
Article Multidisciplinary Sciences

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients

Aliki Ntzifa et al.

Summary: Liquid biopsy was used to investigate gene expression changes in CTC-enriched fractions of EGFR-mutant NSCLC patients treated with osimertinib. The study found correlations between epithelial and stem cell profile, mesenchymal/EMT and stem cell profile at progression of disease, as well as a strong positive correlation of VIM expression with PIM-1 expression at baseline and increased PD-L1 expression levels at progression of disease.

SCIENTIFIC REPORTS (2021)

Add to Collection
Review Oncology

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Zi Yin et al.

Summary: Exosomes, specifically those derived from cancer cells, contain immunosuppressive proteins such as PD-L1, which can hinder immune responses and promote tumor progression. Blocking the interaction between PD-1 and PD-L1 can enhance the efficacy of cancer treatment by restoring anti-tumor immunity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Immunology

Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis

Xingxing Yu et al.

Summary: The study found that serum sPD-1 levels in AP patients increased significantly at certain time points after onset, with higher levels in patients with ICs. sPD-L1 levels in AP were similar to healthy volunteers. Serum sPD-1 level was identified as an independent risk factor for predicting ICs in AP patients.

IMMUNITY INFLAMMATION AND DISEASE (2021)

Add to Collection
Article Hematology

Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma

Johanna Veldman et al.

Summary: In this study, it was found that plasma levels of PD-L1 in classical Hodgkin lymphoma patients were correlated with clinical parameters and strongly associated with PD-L1 expression in the tumor microenvironment. Additionally, a positive correlation between VEGF and PD-1 levels in tissue and plasma was observed.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection
Article Oncology

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte

Baojuan Han et al.

Summary: This study investigated the clinical prognosis and biological function of plasma soluble programmed cell death ligand 1 in breast cancer patients. Results showed that high levels of sPD-L1 and visceral metastasis were independent factors associated with poor prognosis. Additionally, sPD-L1 was found to inhibit T lymphocyte function, playing a negative regulatory role in cellular immunity.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection
Article Chemistry, Medicinal

Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction

Yang Yang et al.

Summary: The study synthesized a novel series of 4-phenylindoline derivatives and evaluated their inhibitory activity against PD-1/PD-L1 protein-protein interaction through HTRF assay. A20 and A22 showed potent activity, with A20 demonstrating promising inhibitory activity in a co-culture model. The study also concluded the structure-activity relationships of the derivatives and analyzed the binding mode of A22 with PD-L1 protein by molecular simulation.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection
Article Medicine, Research & Experimental

PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury

Evangelos Triantafyllou et al.

Summary: The PD-1/PD-L1 pathway regulates KC and monocyte antimicrobial responses after acute liver injury, suppressing immune response and increasing susceptibility to infections.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Opinion PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies

Christopher D. Nishimura et al.

Summary: This article discusses the ligand-ligand cis-interaction between PD-L1 and B7-1 and its impact on immune checkpoint pathways, suggesting significant crosstalk between these pathways and providing new insights for immunotherapies and treatments.

TRENDS IN MOLECULAR MEDICINE (2021)

Add to Collection
Article Oncology

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

Fengling Wang et al.

Summary: The small molecule inhibitor APBC can effectively interrupt the PD-1/PD-L1 interaction, showing promising potential for cancer immunotherapy by enhancing T cell functions. Additionally, APBC demonstrates superior antitumor efficacy in mouse models without inducing observable liver toxicity, making it a promising drug candidate for tumor immunotherapy.

NEOPLASIA (2021)

Add to Collection
Article Medicine, General & Internal

Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study

Renate Pichler et al.

Summary: Despite the low expression of PD-L1 in both tumor regions and cell types, high expression of ADAM17 was found in RC specimens obtained after BCG failure. Additionally, increased expression of GATA3, IL-10, and IL-10R suggested an immunosuppressive tumor microenvironment in BCG failure patients. This study highlights the potential role of ADAM proteases in cleaving PD-L1 from bladder tumor cells and immune cells in BCG failure cases, indicating the necessity of supplementing PD-L1 assessment with ADAM10/17.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection
Article Oncology

Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma

Gorka Larrinaga et al.

Summary: This study revealed the independent predictive role of sPD-L1, as well as the lack of association between sPD-1 and sPD-L1 with clinicopathological parameters. Higher levels of sPD-1 and sPD-L1 were found in patients with synchronous metastases, indicating their potential as biomarkers for metastasis detection.

CANCERS (2021)

Add to Collection
Article Oncology

Prediction of Clinical Outcome in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy by Plasma Markers

Xin Sui et al.

Summary: The study found that high levels of IL-13 and TNF-alpha, and low levels of ICAM-1 in plasma were significantly associated with objective response in patients with locally advanced NSCLC. IL-8 and ICAM-1 were potential markers for predicting PFS.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Article Oncology

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Filippo G. Dall'Olio et al.

Summary: This study found that PD-L1 expression on CTCs is correlated with overall survival in lung cancer patients, while CTC number is associated with baseline tumor size.

CLINICAL LUNG CANCER (2021)

Add to Collection
Article Hematology

Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies

Julie B. Mortensen et al.

Summary: This study provides a comprehensive characterization of pretherapeutic sPD-1, sPD-L1, and sPD-L2 in various lymphoma subtypes. The association between high sPD-1 levels and adverse prognostic factors suggests a potential biological role and clinical usefulness of sPD-1. The opposite expression patterns in follicular lymphoma and T-cell lymphoma/leukemia may provide relevant biological information for immunotherapy targeting the PD-1 pathway.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Add to Collection
Article Oncology

The expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer

Wei Wang et al.

Summary: PD-L1 has been identified as a key immune intervention target for lung cancer treatment. The study found that smoking index, pathological diagnosis, and clinical stage are independent factors influencing PD-L1 expression. Treatment methods such as first-line chemotherapy and targeted therapy affect the count of circulating tumor cells, but do not affect the expression of PD-L1.

FUTURE ONCOLOGY (2021)

Add to Collection
Article Immunology

Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma

Tudor Mocan et al.

Summary: This study found that high sPD-L1 levels are associated with poorer outcomes in hepatocellular carcinoma patients. There was a correlation between sPD-L1 and PD-L1 expression, but fluctuations in sPD-L1 over time did not impact survival. Further research should investigate the predictive value of sPD-L1 levels for successful anti-PD1/PD-L1 therapy.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection
Review Oncology

Immunotherapy and predictive immunologic profile: the tip of the iceberg

Tatiana Cunha Pereira et al.

Summary: The interplay between cancer and the immune system, particularly with the use of immune checkpoint inhibitors, has shown promising results in changing tumor outcomes. However, resistance to immunotherapy remains a challenge for a significant percentage of patients. Predictive biomarkers such as PD-L1 expression and tumor mutational burden are recognized, but more exploration is needed to understand the diversity and complexity within the tumor microenvironment and immune cell interactions.

MEDICAL ONCOLOGY (2021)

Add to Collection
Article Biotechnology & Applied Microbiology

Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer

Yanli Qu et al.

Summary: The study found that the serum sPD-L1 expression level in NSCLC patients decreased after radiotherapy, and the PD-1/PD-L1 pathway may play important roles in NSCLC procession through the Akt/mTOR and HIF-1 alpha pathway.

BIOMED RESEARCH INTERNATIONAL (2021)

Add to Collection
Article Immunology

Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients

Qiao Yang et al.

Summary: This study found that increased expression of PD-L1 mRNA and exoPD-L1 in the early stage of ICIs treatment may serve as positive biomarkers of efficacy and overall survival in advanced NSCLC patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Review Medicine, General & Internal

Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives

Pasquale Persico et al.

Summary: Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with no effective treatment currently available. While immune checkpoint inhibitors (ICI) have shown success in other malignancies, they have not yet made an impact in neuro-oncology. This review summarizes the status of ICI investigation in high-grade gliomas and explores new approaches and potential biomarkers.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection
Article Microbiology

Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma

Kina Kase et al.

Summary: The study found that LMP1 can induce the expression of sPD-L1 and PD-L1 in vitro and that the expression of LMP1 is significantly correlated with PD-L1 in NPC patients. Additionally, the serum level of sPD-L1 in NPC patients was higher than in controls, particularly in advanced stage patients. However, the expression of LMP1, PD-L1, and sPD-L1 levels were not associated with prognosis.

MICROORGANISMS (2021)

Add to Collection
Review Chemistry, Medicinal

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?

Laura Jimbu et al.

Summary: Checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors, have shown promising results in various solid cancers and hematologic diseases. However, their effectiveness in treating AML is limited, possibly due to disease characteristics and immune system dysregulation, warranting further research for optimal use.

PHARMACEUTICALS (2021)

Add to Collection
Article Pathology

Inverse correlation between PD-L1 expression and LGR5 expression in tumor budding of stage II/III colorectal cancer

Koichi Sato et al.

Summary: The study found that PD-L1-positive patients typically have lower LGR5 expression, and in the PD-L1 positive group, TILs score tended to be higher while TNM stage tended to be lower compared with the PD-L1 negative group. There was no significant difference in Overall Survival between PD-L1-positive and PD-L1-negative groups.

ANNALS OF DIAGNOSTIC PATHOLOGY (2021)

Add to Collection
Review Immunology

PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer

Yuxiang Chen et al.

Summary: Colorectal cancer is a common malignant tumor of the digestive system, often diagnosed at an advanced stage. Immune checkpoint inhibitors, like PD-1 and PD-L1 inhibitors, are only effective for some CRC patients, with tumor subtype influencing treatment responses.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection
Article Medical Laboratory Technology

Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer

Weigen Wu et al.

Summary: This study confirmed the potential of serum soluble PD-L1, PD-L2, and B7-H5 as novel biomarkers for diagnosing pancreatic cancer, and their combination with CA19-9 could improve diagnostic sensitivity and specificity.

CLINICAL LABORATORY (2021)

Add to Collection
Article Biotechnology & Applied Microbiology

PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity

Shuang Qu et al.

Summary: This study revealed that lung adenocarcinoma produces a long non-coding RNA isoform of PD-L1 through alternative splicing, which promotes tumor progression by enhancing c-Myc activity. Both in vitro and in vivo studies demonstrated that PD-L1-lnc increases proliferation and invasion while decreasing apoptosis of lung adenocarcinoma cells. Therefore, combining PD-L1-lnc depletion with PD-L1 blockade may be an effective strategy for lung cancer therapy.

GENOME BIOLOGY (2021)

Add to Collection
Article Medicine, Research & Experimental

Therapeutic Effect of an Anti-Human Programmed Death-Ligand 1 (PD-L1) Nanobody on Polymicrobial Sepsis in Humanized Mice

Zhen-zhen Zhao et al.

Summary: The study showed that KN035 has therapeutic effects in septic mice, improving survival rates and reducing apoptosis in the spleen. KN035 also alleviated lung and liver damage, decreased the number of apoptotic cells in the spleen, and helped eliminate bacteria in the peritoneal cavity.

MEDICAL SCIENCE MONITOR (2021)

Add to Collection
Article Biochemistry & Molecular Biology

KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway

Wenwen Du et al.

Summary: This study demonstrates for the first time that PD-L1 regulates NSCLC cell proliferation through the Gas6/MerTK signaling pathway, and reveals a molecular mechanism by which PD-L1 translocates into the nucleus to promote Gas6 synthesis and activate the MerTK signaling pathway. These findings provide potential implications for PD-L1 targeted immunotherapy in the clinic.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection
Review Virology

Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19

Chi Zhang et al.

Summary: The article introduces the potential mechanism of pulmonary fibrosis caused by the COVID-19 virus and discusses the role of three signaling pathways related to fibrosis in the lungs. It also explores the potential therapeutic value of two drugs for COVID-19-induced pulmonary fibrosis.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection
Review Oncology

A snapshot of the PD-1/PD-L1 pathway

Chinmoy Ghosh et al.

Summary: Immune checkpoint blockade is a promising strategy for treating cancer by reactivating anti-tumor immunity, but the response rates and resistance towards current anti-PD-1/PD-L1 therapies remain challenges. New perspectives are needed to overcome these hurdles for successful cancer treatment.

JOURNAL OF CANCER (2021)

Add to Collection
Article Immunology

Maternal soluble PD-1 levels are significantly increased in women with preeclampsia

Yang Gu et al.

AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2020)

Add to Collection
Article Oncology

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Inju Cho et al.

BMC CANCER (2020)

Add to Collection
Article Oncology

Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells

Yeni Romero et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Add to Collection
Article Oncology

PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients

Lina Zhang et al.

CANCER LETTERS (2020)

Add to Collection
Article Oncology

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Manuela Tiako Meyo et al.

CANCERS (2020)

Add to Collection
Article Oncology

Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival

Carla Chiarucci et al.

CANCERS (2020)

Add to Collection
Article Oncology

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas

Shujun Liu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Article Cell Biology

Exosomal PD-L1 functions as an immunosuppressant to promote wound healing

Dandan Su et al.

JOURNAL OF EXTRACELLULAR VESICLES (2020)

Add to Collection
Article Immunology

Modulation of Vaccine-Induced HIV-1-Specific Immune Responses by Co-Electroporation of PD-L1 Encoding DNA

Pierre Tannig et al.

Vaccines (2020)

Add to Collection
Review Pharmacology & Pharmacy

Protein homodimer sequestration with small molecules: Focus on PD-L1

Christian Bailly et al.

BIOCHEMICAL PHARMACOLOGY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Prognostic value of programmed cell death ligand (PD-L1) for hepatocellular carcinoma: a meta-analysis

Xiao-Song Li et al.

BIOSCIENCE REPORTS (2020)

Add to Collection
Article Cell Biology

Regulation of sister chromatid cohesion by nuclear PD-L1

Jia Yu et al.

CELL RESEARCH (2020)

Add to Collection
Review Oncology

Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)

Finn Mildner et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)

Add to Collection
Review Pharmacology & Pharmacy

Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis

Xuewen Wang et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection
Article Immunology

Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity

Yan Du et al.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2020)

Add to Collection
Article Medicine, General & Internal

Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure

Jose Avendano-Ortiz et al.

MEDICINE (2020)

Add to Collection
Review Immunology

Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma

Hinrich P. Hansen et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Review Immunology

The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer

Yanyan Tang et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Article Oncology

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters

Angelo Castello et al.

CANCERS (2020)

Add to Collection
Article Dentistry, Oral Surgery & Medicine

Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus

Nadia Lago Costa et al.

ORAL DISEASES (2020)

Add to Collection
Article Immunology

Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility

Budi Santoso et al.

AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2020)

Add to Collection
Article Cell & Tissue Engineering

Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy

Ang Zhang et al.

CYTOTHERAPY (2020)

Add to Collection
Article Oncology

Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels ofPD-L1 mRNAand solublePD-L1

Yu Feng et al.

HEMATOLOGICAL ONCOLOGY (2020)

Add to Collection
Article Oncology

Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients

Yusuke Omura et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Add to Collection
Review Biochemistry & Molecular Biology

ADAM-Mediated Signalling Pathways in Gastrointestinal Cancer Formation

Neele Schumacher et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection
Article Medicine, General & Internal

Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women

Matyas Meggyes et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection
Review Oncology

The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials

Alberto Carretero-Gonzalez et al.

CANCERS (2020)

Add to Collection
Article Oncology

Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients

Jiabei He et al.

JOURNAL OF IMMUNOTHERAPY (2020)

Add to Collection
Article Multidisciplinary Sciences

Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas

Kunihiro Asanuma et al.

SCIENTIFIC REPORTS (2020)

Add to Collection
Article Medicine, Research & Experimental

PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs

Milad Ashrafizadeh et al.

LIFE SCIENCES (2020)

Add to Collection
Article Oncology

Soluble PD-L1 and Circulating CD8+PD-1+and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

G. Mazzaschi et al.

LUNG CANCER (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy

Jie Xu et al.

ONCOGENE (2020)

Add to Collection
Article Oncology

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

Jacob J. Orme et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Article Oncology

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients WithEGFRMutations

Yijun Jia et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Review Cell & Tissue Engineering

Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome

Feng Lin et al.

WORLD JOURNAL OF STEM CELLS (2020)

Add to Collection
Review Cell Biology

Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies

Kaijian Zhou et al.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

Add to Collection
Article Immunology

Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination

Pierre Tannig et al.

VACCINES (2020)

Add to Collection
Article Chemistry, Medicinal

Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors

Binbin Cheng et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection
Review Immunology

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy

Muhammad Khan et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Review Oncology

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

Boris Duchemann et al.

CANCERS (2020)

Add to Collection
Article Oncology

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

Christopher Montemagno et al.

ONCOIMMUNOLOGY (2020)

Add to Collection
Article Immunology

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes

Xing-Chen Ding et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Review Cell Biology

PD-L1 degradation pathway and immunotherapy for cancer

Qian Gou et al.

CELL DEATH & DISEASE (2020)

Add to Collection
Article Oncology

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody

Shuji Murakami et al.

THORACIC CANCER (2020)

Add to Collection
Article Oncology

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients

Yue Fei et al.

JOURNAL OF CANCER (2020)

Add to Collection
Article Immunology

Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity

Min Tong et al.

IMMUNOLOGY LETTERS (2020)

Add to Collection
Article Cell Biology

Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages

Jing Xu et al.

CELL DEATH & DISEASE (2020)

Add to Collection
Article Immunology

Matrix metalloproteinases cleave membrane-bound PD-L1 on CD90+ (myo-)fibroblasts in Crohn's disease and regulate Th1/Th17 cell responses

Jose E. Aguirre et al.

INTERNATIONAL IMMUNOLOGY (2020)

Add to Collection
Review Materials Science, Biomaterials

Immune Escape Mediated by Exosomal PD-L1 in Cancer

Sean E. Lawler et al.

ADVANCED BIOSYSTEMS (2020)

Add to Collection
Review Oncology

Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy

Samantha M. Morrissey et al.

TRENDS IN CANCER (2020)

Add to Collection
Article Oncology

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

Jacob J. Orme et al.

ONCOIMMUNOLOGY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times

Christian Bailly et al.

NAR CANCER (2020)

Add to Collection
Article Oncology

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours

Maximilian J. Mair et al.

ESMO OPEN (2020)

Add to Collection
Article Critical Care Medicine

INTEGRIN AND PD-1 LIGAND EXPRESSION ON CIRCULATING EXTRACELLULAR VESICLES IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AND SEPSIS

Eiji Kawamoto et al.

SHOCK (2019)

Add to Collection
Article Critical Care Medicine

PREDICTIVE VALUE OF SOLUBLE PROGRAMMED DEATH-1 FOR SEVERE SEPSIS AND SEPTIC SHOCK DURING THE FIRST WEEK IN AN INTENSIVE CARE UNIT

Yongzhen Zhao et al.

SHOCK (2019)

Add to Collection
Article Oncology

Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma

Xue Han et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Add to Collection
Article Biophysics

A SERS microfluidic platform for targeting multiple soluble immune checkpoints

K. Kamil Reza et al.

BIOSENSORS & BIOELECTRONICS (2019)

Add to Collection
Article Oncology

Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5

Ziqian Li et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

Add to Collection
Article Immunology

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer

Bo Gong et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2019)

Add to Collection
Article Biotechnology & Applied Microbiology

Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice

Thomas D. Norton et al.

MOLECULAR THERAPY (2019)

Add to Collection
Review Biochemistry & Molecular Biology

Exosomes in cancer development, metastasis, and immunity

Lin Zhang et al.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)

Add to Collection
Article Oncology

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas

Xuhan Zhang et al.

HEMATOLOGICAL ONCOLOGY (2019)

Add to Collection
Article Oncology

Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer

Juichiro Yoshida et al.

MEDICAL ONCOLOGY (2019)

Add to Collection
Article Biochemistry & Molecular Biology

PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy

Xinyi Tu et al.

MOLECULAR CELL (2019)

Add to Collection
Article Medical Laboratory Technology

Metalloproteinases at the surface of small extrcellular vesicles in advanced ovarian cancer: Relationships with ascites volume and peritoneal canceromatosis index

Natalia Yunusova et al.

CLINICA CHIMICA ACTA (2019)

Add to Collection
Article Oncology

Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients

Fatma El-Gebaly et al.

CURRENT CANCER DRUG TARGETS (2019)

Add to Collection
Article Multidisciplinary Sciences

Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma

Megumi Goto et al.

SCIENTIFIC REPORTS (2019)

Add to Collection
Article Endocrinology & Metabolism

Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer

Marra Jai Aghajani et al.

ENDOCRINE CONNECTIONS (2019)

Add to Collection
Review Cell Biology

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

Vera Kloten et al.

CELLS (2019)

Add to Collection
Article Oncology

Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors

Kiyohiro Ando et al.

ANTICANCER RESEARCH (2019)

Add to Collection
Review Oncology

The clinical significance of soluble PD-1 and PD-L1 in lung cancer

Taher Abu Hejleh et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)

Add to Collection
Article Medicine, General & Internal

Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC) A preliminary study

Jia Yang et al.

MEDICINE (2019)

Add to Collection
Article Biochemical Research Methods

Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings

Binbin Luo et al.

BIOMEDICAL OPTICS EXPRESS (2019)

Add to Collection
Review Medicine, General & Internal

Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?

JanWillem Duitman et al.

JOURNAL OF CLINICAL MEDICINE (2019)

Add to Collection
Review Oncology

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Adrien Costantini et al.

CANCERS (2019)

Add to Collection
Article Medicine, Research & Experimental

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Chuling Li et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2019)

Add to Collection
Review Biochemistry & Molecular Biology

The role of exosomal PD-L1 in tumor progression and immunotherapy

Feiting Xie et al.

MOLECULAR CANCER (2019)

Add to Collection
Article Biology

Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist

Kevin W. Ng et al.

ELIFE (2019)

Add to Collection
Article Oncology

Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression

Tsunehiko Shigemori et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

Add to Collection
Review Immunology

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer

Weiting Qin et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection
Review Cell Biology

Regulation of Fibrotic Processes in the Liver by ADAM Proteases

Dirk Schmidt-Arras et al.

CELLS (2019)

Add to Collection
Article Oncology

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer

Paul Buderath et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection
Article Oncology

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Kathleen M. Mahoney et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

Add to Collection
Article Oncology

Identification and characterization of an alternative cancer-derived PD-L1 splice variant

Nadia B. Hassounah et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

Add to Collection
Article Respiratory System

Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients

Carolina Cubillos-Zapata et al.

EUROPEAN RESPIRATORY JOURNAL (2019)

Add to Collection
Article Respiratory System

Age-dependent hypoxia-induced PD-L1 upregulation in patients with obstructive sleep apnoea

Carolina Cubillos-Zapata et al.

RESPIROLOGY (2019)

Add to Collection
Review Medicine, General & Internal

Basis of PD1/PD-L1 Therapies

Barbara Seliger

JOURNAL OF CLINICAL MEDICINE (2019)

Add to Collection
Article Immunology

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)

Vishwanatha R. A. P. Reddy et al.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)

Add to Collection
Article Immunology

Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction

Mai Okuyama et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection
Article Chemistry, Analytical

Single droplet detection of immune checkpoints on a multiplexed electrohydrodynamic biosensor

Alain Wuethrich et al.

ANALYST (2019)

Add to Collection
Review Medicine, General & Internal

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies

Yumi Kambayashi et al.

FRONTIERS IN MEDICINE (2019)

Add to Collection
Article Oncology

Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage

Mayuko Hira-Miyazawa et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2018)

Add to Collection
Review Oncology

Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients

A. Mitsuhashi et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2018)

Add to Collection
Review Biochemistry & Molecular Biology

Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments

Stefan F. Lichtenthaler et al.

EMBO JOURNAL (2018)

Add to Collection
Article Immunology

Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer

Masahiro Takeuchi et al.

IMMUNOLOGY LETTERS (2018)

Add to Collection
Review Medicine, General & Internal

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors A meta-analysis

Wei Wei et al.

MEDICINE (2018)

Add to Collection
Review Oncology

Biomarkers for checkpoint inhibition in hematologic malignancies

Djordje Atanackovic et al.

SEMINARS IN CANCER BIOLOGY (2018)

Add to Collection
Article Biotechnology & Applied Microbiology

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia

Yingying Wang et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)

Add to Collection
Article Oncology

PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface

Apoorvi Chaudhri et al.

CANCER IMMUNOLOGY RESEARCH (2018)

Add to Collection
Article Immunology

Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals

A. Leon-Flores et al.

IMMUNOLOGY LETTERS (2018)

Add to Collection
Article Multidisciplinary Sciences

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Gang Chen et al.

NATURE (2018)

Add to Collection
Editorial Material Immunology

Hiding in Plain Sight: Soluble Immunomodulatory Receptors

Lekh N. Dahal et al.

TRENDS IN IMMUNOLOGY (2018)

Add to Collection
Article Immunology

Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis

Caroline Wasen et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Article Oncology

Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200

Michael Koukourakis et al.

ANTICANCER RESEARCH (2018)

Add to Collection
Article Respiratory System

Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study

Dragana Jovanovic et al.

JOURNAL OF THORACIC DISEASE (2018)

Add to Collection
Article Immunology

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism

Martin J. Raftery et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Article Hematology

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

Shahrzad Jalali et al.

BLOOD ADVANCES (2018)

Add to Collection
Article Oncology

Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients

Marie-Nicole Theodoraki et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection
Article Immunology

Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy

Elizabeth Ann L. Enninga et al.

AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2018)

Add to Collection
Article Critical Care Medicine

Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study

Julie K. Wilson et al.

CRITICAL CARE (2018)

Add to Collection
Article Gastroenterology & Hepatology

Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis

Kristian Aarslev et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2017)

Add to Collection
Review Immunology

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3

Murali Janakiram et al.

IMMUNOLOGICAL REVIEWS (2017)

Add to Collection
Article Medicine, General & Internal

Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C

Satoshi Yamagiwa et al.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2017)

Add to Collection
Article Surgery

Anti-PD-L1 peptide improves survival in sepsis

Yuichiro Shindo et al.

JOURNAL OF SURGICAL RESEARCH (2017)

Add to Collection
Article Immunology

sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis

Y. Chen et al.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2017)

Add to Collection
Article Oncology

High-affinity human PD-L1 variants attenuate the suppression of T cell activation

Zhaoduan Liang et al.

ONCOTARGET (2017)

Add to Collection
Review Oncology

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

Xinxin Zhu et al.

ONCOTARGET (2017)

Add to Collection
Article Oncology

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Jun Zhou et al.

CANCER IMMUNOLOGY RESEARCH (2017)

Add to Collection
Article Oncology

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

Stephan Kruger et al.

ONCOIMMUNOLOGY (2017)

Add to Collection
Article Critical Care Medicine

Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis

Tingting Pan et al.

CRITICAL CARE (2017)

Add to Collection
Article Immunology

Inflammatory cytokines compromise programmed cell death-1(PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1

D. Bommarito et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)

Add to Collection
Article Oncology

A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage

Colette Dezutter-Dambuyant et al.

ONCOIMMUNOLOGY (2016)

Add to Collection
Article Oncology

Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer

Naoki Takahashi et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)

Add to Collection
Article Dermatology

Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis

Koichi Yanaba et al.

JOURNAL OF DERMATOLOGY (2016)

Add to Collection
Article Medicine, Research & Experimental

Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS)

Sean F. Monaghan et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2016)

Add to Collection
Article Oncology

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy

Hyerim Ha et al.

ONCOTARGET (2016)

Add to Collection
Article Oncology

Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility

Barbora Brodska et al.

CANCER IMMUNOLOGY RESEARCH (2016)

Add to Collection
Article Hematology

Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis

Elif Birtas Atesoglu et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2016)

Add to Collection
Article Rheumatology

Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways

Cuiping Liu et al.

ARTHRITIS RESEARCH & THERAPY (2015)

Add to Collection
Article Genetics & Heredity

The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis

Q. Yao et al.

INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2015)

Add to Collection
Article Multidisciplinary Sciences

HIV-1 Tat Protein Induces Production of Proinflammatory Cytokines by Human Dendritic Cells and Monocytes/Macrophages through Engagement of TLR4-MD2-CD14 Complex and Activation of NF-κB Pathway

Nawal Ben Haij et al.

PLOS ONE (2015)

Add to Collection
Article Virology

HIV-1 Tat Protein Induces PD-L1 (B7-H1) Expression on Dendritic Cells through Tumor Necrosis Factor Alpha-and Toll-Like Receptor 4-Mediated Mechanisms

Remi Planes et al.

JOURNAL OF VIROLOGY (2014)

Add to Collection
Article Rheumatology

Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis

S. R. Greisen et al.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2014)

Add to Collection
Article Endocrinology & Metabolism

Increased PD-1 on CD4+CD28- T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases

Bimin Shi et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2013)

Add to Collection
Article Oncology

Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

Xavier Frigola et al.

CLINICAL CANCER RESEARCH (2011)

Add to Collection
Article Cell Biology

A dimeric structure of PD-L1: functional units or evolutionary relics?

Yong Chen et al.

PROTEIN & CELL (2010)

Add to Collection
Article Rheumatology

Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus

M. Her et al.

LUPUS (2009)

Add to Collection
Article Biochemistry & Molecular Biology

Interaction of human PD-L1 and B7-1

Manish J. Butte et al.

MOLECULAR IMMUNOLOGY (2008)

Add to Collection
Article Chemistry, Multidisciplinary

Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain

XH He et al.

ACTA PHARMACOLOGICA SINICA (2005)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.